IRWD Ironwood Pharmaceuticals
- 4.400
- -0.040-0.90%
- 4.400
- 0.0000.00%
Ironwood Pharmaceuticals News
Capital One Financial Downgrades Ironwood Pharmaceuticals(IRWD.US) to Hold Rating, Cuts Target Price to $5
Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Announces Target Price $12
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $23
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
Leerink Partners Initiates Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Announces Target Price $5
Ironwood Pharmaceuticals Analyst Ratings
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $10
Ironwood Pharma (IRWD) Gets a Buy From JMP Securities
Ironwood Pharmaceuticals: Hold Rating Amidst Financial and Market Headwinds
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
Ironwood Pharmaceuticals Analyst Ratings
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Ironwood Pharmaceuticals: A Buy Rating Amidst Strong Product Positioning and Promising Clinical Data
Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals Receives 'Buy' Rating From Analyst Amid Strong Performance and Promising Drug Pipeline
Ironwood Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
No Data